© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Axonics, Inc. (AXNX) stock remained unchanged at -, trading at $70.98 on NASDAQ, unchanged from the previous close of -. The stock opened at -, fluctuating between $70.98 and $70.98 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 15, 2024 | 70.98 | 70.98 | 70.98 | 70.98 | 0 |
| Nov 14, 2024 | 70.50 | 71.05 | 70.37 | 70.98 | 4.15M |
| Nov 13, 2024 | 70.57 | 70.57 | 70.45 | 70.45 | 243.13K |
| Nov 12, 2024 | 70.44 | 70.58 | 70.44 | 70.49 | 353.82K |
| Nov 11, 2024 | 70.43 | 70.58 | 70.40 | 70.48 | 501.63K |
| Nov 08, 2024 | 70.48 | 70.50 | 70.40 | 70.42 | 233.84K |
| Nov 07, 2024 | 70.41 | 70.48 | 70.36 | 70.45 | 438.42K |
| Nov 06, 2024 | 70.46 | 70.75 | 70.39 | 70.48 | 735.9K |
| Nov 05, 2024 | 70.36 | 70.43 | 70.28 | 70.31 | 528.7K |
| Nov 04, 2024 | 70.37 | 70.48 | 70.33 | 70.38 | 289.03K |
| Nov 01, 2024 | 70.45 | 70.45 | 70.29 | 70.37 | 506.44K |
| Oct 31, 2024 | 70.34 | 70.44 | 70.15 | 70.30 | 280K |
| Oct 30, 2024 | 70.29 | 70.34 | 70.07 | 70.29 | 267.13K |
| Oct 29, 2024 | 70.14 | 70.31 | 70.14 | 70.24 | 309.03K |
| Oct 28, 2024 | 70.37 | 70.37 | 70.14 | 70.24 | 491.81K |
| Oct 25, 2024 | 70.30 | 70.35 | 69.95 | 70.23 | 847.11K |
| Oct 24, 2024 | 70.23 | 70.43 | 70.23 | 70.28 | 434.2K |
| Oct 23, 2024 | 70.27 | 70.31 | 70.23 | 70.27 | 321.81K |
| Oct 22, 2024 | 70.24 | 70.31 | 70.20 | 70.29 | 170.2K |
| Oct 21, 2024 | 70.23 | 70.30 | 70.23 | 70.28 | 240.45K |
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
| Employees | 797 |
| Beta | 0.83 |
| Sales or Revenue | $366.38M |
| 5Y Sales Change% | 72.885% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Devices |